Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Procaps Group S.A. (PROC)

Procaps Group S.A. (PROC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 113,952
  • Shares Outstanding, K 112,824
  • Annual Sales, $ 409,920 K
  • Annual Income, $ 42,540 K
  • EBIT $ 34 M
  • EBITDA $ 51 M
  • 60-Month Beta -0.05
  • Price/Sales 0.25
  • Price/Cash Flow 1.92
  • Price/Book 2.96
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.52
  • Most Recent Earnings N/A on 12/26/23
  • Next Earnings Date 01/01/70
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $0.08
  • Growth Rate Est. (year over year) +1,248,650.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7742 +30.46%
on 02/03/25
2.2400 -54.91%
on 01/06/25
-1.2400 (-55.11%)
since 01/03/25
3-Month
0.5000 +102.00%
on 11/19/24
3.7750 -73.25%
on 12/17/24
-0.7750 (-43.42%)
since 11/01/24
52-Week
0.5000 +102.00%
on 11/19/24
3.8400 -73.70%
on 02/16/24
-2.7000 (-72.78%)
since 02/02/24

Most Recent Stories

More News
Procaps Group Strengthens Financial Position Through Strategic Transactions and Governance Updates

Procaps Group announces strategic transactions to bolster financial stability, governance updates, and a $40 million secured convertible note issuance.Quiver AI SummaryProcaps Group, S.A. announced significant...

PROC : 1.0100 (-36.51%)
Procaps Group Receives Nasdaq Delisting Notice Due to Late Filing of Form 20-F

Procaps Group faces potential Nasdaq delisting for late filing of Form 20-F but plans to request a hearing.Quiver AI SummaryProcaps Group, S.A. announced that it received notice from Nasdaq regarding its...

PROC : 1.0100 (-36.51%)
Donaldson: Fiscal Q4 Earnings Snapshot

Donaldson: Fiscal Q4 Earnings Snapshot

PROC : 1.0100 (-36.51%)
Procaps Group Reports Preliminary First Quarter 2022 Results

Net Revenues Increased by 11% to U$ 86 million, with Adjusted EBITDA Up 15% Year-Over-Year to $9 Million...

PROC : 1.0100 (-36.51%)
Procaps Group to Acquire Grupo Somar (including Química y Farmacia, Gelcaps and related entities) from Advent International, gaining an important presence in Mexico, the Region's Second Largest Market

This acquisition reaffirms Procaps Groups’ strategy to become one of the fastest growing pharmaceutical organizations in Latin America With FY2021 Net...

PROC : 1.0100 (-36.51%)
Procaps Group Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Procaps Group S.A. (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced its financial results for the fourth quarter and fiscal year ended...

PROC : 1.0100 (-36.51%)
PROCW : 0.0194 (-35.33%)

Business Summary

Procaps Group is a developer of pharmaceutical and nutraceutical solutions, medicines and hospital supplies. It develops, manufactures and markets over-the-counter and prescription drugs, nutritional supplements and high-potency clinical solutions. Procaps Group, formerly known as Union Acquisition Corp....

See More

Key Turning Points

3rd Resistance Point 1.9244
2nd Resistance Point 1.6472
1st Resistance Point 1.3286
Last Price 1.0100
1st Support Level 0.7328
2nd Support Level 0.4556
3rd Support Level 0.1370

See More

52-Week High 3.8400
Fibonacci 61.8% 2.5641
Fibonacci 50% 2.1700
Fibonacci 38.2% 1.7759
Last Price 1.0100
52-Week Low 0.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.